SLDB Solid Biosciences Inc.
Price Chart
Executive Summary
Solid Biosciences announced positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, showing robust microdystrophin expression and biomarker improvements in Duchenne muscular dystrophy patients. The company also confirmed FDA alignment on the Phase 3 IMPACT DUCHENNE trial design, with dosing expected to begin in Q1 2026.
Actionable Insight
This data strengthens SGT-003's differentiation and supports potential for accelerated approval. Traders should monitor upcoming FDA meetings in H1 2026 for guidance on accelerated approval pathway and mid-2026 clinical updates.
Key Facts
- SGT-003 showed 60% mean microdystrophin expression by western blot at Day 90 (n=19), increasing to 91% at Day 360 (n=3)
- Mean vector copies per nucleus were 11 at Day 90 and 12 at Day 360, indicating stable transduction
- Key biomarkers showed significant improvement: 38% mean reduction in serum creatine kinase (CK) at Day 90, 44% reduction in eMHC-positive fibers suggesting disruption of degeneration-regeneration cycle
- FDA has agreed the Phase 3 IMPACT DUCHENNE trial design is reasonable, with dosing expected in Q1 2026
- SGT-003 is the only microdystrophin therapy with the R16/R17 binding domain that localizes nNOS to muscle
Financial Impact
No direct financial impact disclosed, but clinical progress significantly de-risks development path for SGT-003
Risk Factors
- Interim data from small samples (n=3 at Day 360) may not be predictive of final outcomes
- Phase 3 trial results may not replicate Phase 1/2 findings
- Company remains dependent on raising substantial additional capital to continue development
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-102489 |
| Document: 0001193125-26-102489-index-headers.html | 0001193125-26-102489 |
| Document: 0001193125-26-102489-index.html | 0001193125-26-102489 |
| Document: 0001193125-26-102489.txt | 0001193125-26-102489 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 12, 2026
4w ago
|
Press Release
| $7.38 $6.08 | ▲ +17.62% | ▲ +16.46% | $7.14 (+3.25%) |
|
May 7, 2026
5w ago
|
Press Release
| $7.07 $7.38 | ▲ +4.38% | ▲ +2.88% | $7.14 (+0.99%) |
|
Apr 23, 2026
7w ago
|
DEFA14A
| $7.92 $7.26 | ▼ −8.33% | ▼ −9.24% | $7.14 (−9.85%) |
|
Apr 10, 2026
9w ago
|
8-K
| $8.39 $8.49 | ▲ +1.19% | ▼ −2.10% | $7.14 (−14.90%) |
|
Apr 1, 2026
10w ago
|
EFFECT
| $7.38 $8.10 | ▼ −9.76% | ▼ −5.99% | $7.14 (+3.25%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $7.03 $7.11 | ▲ +1.14% | ▲ +3.29% | $7.14 (+1.56%) |
|
Mar 12, 2026
13w ago
|
8-K
| $7.71 $7.12 | ▼ −7.65% | ▼ −6.67% | $7.14 (−7.39%) |
|
Mar 11, 2026
13w ago
|
Press Release
| $7.72 $7.12 | ▼ −7.71% | ▼ −5.52% | $7.14 (−7.45%) |
|
Mar 6, 2026
14w ago
|
Press Release
| $6.75 $7.31 | ▲ +8.30% | ▲ +9.82% | $7.14 (+5.78%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $5.96 $8.18 | ▲ +37.25% | ▲ +37.73% | $7.14 (+19.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access